en · de · es
bpc-157-notes.peptides5388.com › Wiki › Bpc-157 Identity And Origin — Deep Dive

Bpc-157 Identity And Origin — Deep Dive

By Editorial Desk · published 2026-07-24 · last reviewed 2026-08-01 · Wiki

If you have been reading about Research material and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

BPC-157 Identity and Origin

Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.

BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.

Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.

Background, Origin, and Naming

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Bpc-157 at a glance

PropertyValueNotes
ClassSynthetic peptideLinear, fifteen residues
SequenceGEPPPGKPADDAGLVSingle-letter amino acid code
Approximate mass1419 DaValue reported for the free peptide
Reported originFragment of a gastric juice proteinUsed as the design template
Common synonymsBody protection compound 157; PL 14736Naming varies across papers and suppliers

Research Literature and Evidence Status

Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.

Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.

Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.

Related pages on this site

Handling, Storage, and Analytical Methods

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.

Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.

Further detail

Using agents which mimic the virus-associated protein (VAP) and bind to the cellular receptors. This may include VAP anti-idiotypic antibodies, natural ligands of the receptor, and anti-receptor antibodies. Using agents which mimic the cellular receptor and bind to the VAP. This includes anti-VAP antibodies, receptor anti-idiotypic antibodies, extraneous receptor and synthetic receptor mimics. This strategy of designing drugs can be very expensive, and since the process of generating anti-idiotypic antibodies is partly trial and error, it can be a relatively slow process until an adequate molecule is produced.

Pseudomonas syringae is a rod-shaped, Gram-negative bacterium with polar flagella. As a plant pathogen, it can infect a wide range of species, and exists as over 50 different pathovars, all of which are available to researchers from international culture collections such as the NCPPB, ICMP, and others. Pseudomonas syringae is a member of the genus Pseudomonas, and based on 16S rRNA analysis, it has been placed in the P. syringae group. It is named after the lilac tree (Syringa vulgaris), from which it was first isolated. A phylogenomic analysis of 494 complete genomes from the entire Pseudomonas genus showed that P. syringae does not form a monophyletic species in the strict sense, but a wider evolutionary group that also included other species as well, such as P. avellanae, P. savastanoi, P. amygdali, and P. cerasi. Pseudomonas syringae tests negative for arginine dihydrolase and oxidase activity, and forms the polymer levan on sucrose nutrient agar. Many, but not all, strains secrete the lipopeptide plant toxin syringomycin, and it owes its yellow fluorescent appearance when cultured in vitro on King's B medium to production of the siderophore pyoverdin. Pseudomonas syringae also produces ice nucleation active (INA) proteins which cause water (in plants) to freeze at fairly high temperatures (−1.8 to −3.8 °C (28.8 to 25.2 °F)), resulting in injury. Since the 1970s, P. syringae has been implicated as an atmospheric biological ice nucleator, with airborne bacteria serving as cloud condensation nuclei.

She was scheduled to make her debut in the musical at the Sunderland Empire Theatre on 31 May and was due to perform in Cardiff, Blackpool, Sheffield, Norwich and Oxford on selected dates throughout June and July. However a week before, it was announced that Collins had been forced to withdraw from the production due to a flare up of her knee injury that she sustained whilst competing on Dancing on Ice. She was replaced by singer and Loose Women panellist Brenda Edwards. In June 2022, Collins appeared in an online segment for the BBC nature series Springwatch. She visited Wild Ken Hill in Norfolk and was accompanied by Chris Packham and Hannah Stitfall, where she discussed her love of plants and wildlife and was advised on how to improve her garden before being given a tour around the site. Collins said she was "honoured" to appear on the show and that she had been overwhelmed by the "beauty of nature". In August 2022, Collins appeared on The Big Breakfast, in a guest segment that featured her assuming the role of an agony aunt and answering viewers' questions. In September 2022, Collins appeared as a guest on the show and was interviewed by Judi Love in the bedroom about her self-confidence, upcoming nuptials as well as dispelling rumours she was set to present the next series of Love Island following an online campaign. Later that month, Collins appeared in marketing campaign for the Channel 4 series Make Me Prime Minister, in which she laid out a satire "GC manifesto" with a list of rules she planned to implement if she became Prime Minister.

=== Synthesis === For the synthesis of alprazolam the same method can be used as for triazolam, except that it starts from 2-amino-5-chlorobenzophenone. However, an alternative easier synthesis starting with 2,6-dichloro-4-phenylquinoline has been suggested, in which it reacts with hydrazine giving 6-chloro-2-hydrazino-4-phenylquinoline. Boiling the mixture with triethyl orthoacetate results in cyclization with the formation of the triazole ring. The product undergoes oxidative degradation in the presence of periodate and ruthenium dioxide in acetone solution, giving 2-[4-(3'-methyl-1,2,4-triazolo)]-5-chlorobenzophenone. Oxy-methylation with formaldehyde results in a product that is treated with phosphorus tribromide when 2-[4-(3'-methyl-5'-bromomethyl-1,2,4-triazolo)]-5-chlorobenzophenone is obtained. By substituting the bromine atom with an amino group conferred by ammonia, it forms alprazolam triazolobenzophenone, following which an intramolecular heterocyclization takes place to obtain alprazolam.

He added that exploring a different vocal palette enabled him to maintain a constant "tension" throughout a song, whereas previously he had alternated between a more relaxed singing style and some "tense" sporadic passages. Toufouti's vocals on Saddiction have been compared to those of Phil Collins. Ronny Bittner of Rock Hard adds that his "soulful singing" brings "some warmth" to the album's overall sound, "through skilful harmonic shifts".

Sources: en.wikipedia.org

Background from the literature

==== UK Information Commissioner's Office ==== In February 2019, the United Kingdom's Information Commissioner's Office (ICO) launched an investigation of TikTok following the fine ByteDance received from the United States Federal Trade Commission (FTC). Speaking to a parliamentary committee, Information Commissioner Elizabeth Denham said that the investigation focuses on the issues of private data collection, the kind of videos collected and shared by children online, as well as the platform's open messaging system which allows any adult to message any child. She noted that the company was potentially violating the GDPR which requires the company to provide different services and different protections for children. In April 2023, the ICO imposed a £12.7 million fine on TikTok for misusing children's data. In March 2025, the ICO opened another investigation into TikTok concerning its use of children's personal information to recommend content to them.

== Research == Progesterone was studied as a progestogen-only injectable contraceptive, but was never marketed. Combinations of estradiol and progesterone as a macrocrystalline aqueous suspension and as an aqueous suspension of microspheres have been studied as once-a-month combined injectable contraceptives, but were likewise never marketed. Progesterone has been assessed for the suppression of sex drive and spermatogenesis in men. In one study, 100 mg rectal suppositories of progesterone given five times per day for 9 days resulted in progesterone levels of 5.5 to 29 ng/mL and suppressed circulating testosterone and growth hormone levels by about 50% in men, but did not affect libido or erectile potency in this short treatment period. In other studies, 50 mg/day progesterone by intramuscular injection for 10 weeks in men produced azoospermia, decreased testicular size, markedly suppressed libido and erectile potency, and resulted in minimal semen volume upon ejaculation. An oil and water nanoemulsion of progesterone (particles of <1 mm in diameter) using micellar nanoparticle technology for transdermal administration known as Progestsorb NE was under development by Novavax for use in menopausal hormone therapy in the 2000s. However, development was discontinued in 2007 and the formulation was never marketed.

In December 2022, the British government announced that it planned to open the Independent Inquiry relating to Afghanistan to investigate extrajudicial killings that took place between 2010 and 2013, during the War in Afghanistan. This followed a detailed BBC Panorama investigation that found members of the SAS "repeatedly killed detainees and unarmed men in suspicious circumstances". Panorama spoke to witnesses who alleged that operatives justified the killings of unarmed persons by leaving weapons at the scenes of the shootings and that SAS squadrons competed '"with each other to get the most kills". According to the investigation, officers of the UK Special Forces were concerned over the number of reports of detainees being killed after reaching for hidden weapons. Allegedly, several raids ended with the deaths of more people than weapons recovered. The BBC visited the sites of some raids and heard from ballistics experts who interpreted the bullet patterns present as more indicative "of execution-style killings rather than firefights". A formal internal review was opened at the time, but evidence was never passed to military police. The inquiry was launched in March 2023, to be chaired by Lord Justice Haddon-Cave. In September 2024, an internal Ministry of Defence document written in 2019 was presented to the inquiry that concluded that the BBC Panorama allegations were "broadly accurate".

adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 chemically?

It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.

Does it occur naturally in the body?

The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.

Is it an approved drug?

No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.

What is BPC-157?

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.

Network